IL-2

 Asher Bio Announces Publications in Cancer Discovery Highlighting the Differentiated Profile of AB248, its CD8+ T Cell Selective IL-2 Product Candidate

Retrieved on: 
Wednesday, April 3, 2024
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, Toxicity, Netherlands Cancer Institute, VLS, Therapeutic index, Cell, Patient, ICB, Neoplasm, Immunology, Hypertelorism, Cancer, Infection, Publication, Immunity, IL-2, NKI, CD8, Immune system, Division, NK, Autoimmunity, PD-1, Vaccine

The papers were authored by Asher Bio scientists and collaborators at The Netherlands Cancer Institute (NKI), respectively, and published online in Cancer Discovery on April 2, 2024.

Key Points: 
  • The papers were authored by Asher Bio scientists and collaborators at The Netherlands Cancer Institute (NKI), respectively, and published online in Cancer Discovery on April 2, 2024.
  • “These co-published manuscripts are the culmination of several years of great collaboration between Asher Bio scientists and our academic co-founders, Dr.
  • Asher Bio systematically evaluated the properties needed for effective cis-targeting to CD8+ T cells and generated AB248, a CD8+ T cell selective IL-2.
  • To evaluate this hypothesis, Asher Bio’s collaborators at the NKI performed a comprehensive analysis of T cell reinvigoration following treatment with AB248.

Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies

Retrieved on: 
Wednesday, November 15, 2023
Rubius, IL-2, Mural, Cytokine, Research, General counsel, Alexion, Therapy, Head, Arbutus Biopharma, Jazz Pharmaceuticals, Patient, Doctor of Philosophy, Protein engineering, Bristol Myers Squibb, Pembrolizumab, IL-12, Alkermes (company), Halozyme, AbbVie, MBA, YM Biosciences, El Rubius, Nivolumab, Ipilimumab, ImClone Systems, Mirati Therapeutics, BMS, Financial toxicity, Mucosal melanoma, FRCP, The Celator, Cancer, PROC, GSK plc, Pharmaceutical industry, Vaccine, Management, Exelixis, Merck, Immunogen

DUBLIN, Ireland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) today launched as an independent, publicly traded, clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Mural’s ordinary shares will begin trading on the Nasdaq Global Market tomorrow, November 16th, under the ticker symbol “MURA”.

Key Points: 
  • “Immunotherapies have made a tremendous impact on the treatment of cancers over the past decade,” said Caroline Loew, Ph.D., the Company’s chief executive officer.
  • We believe Mural Oncology can lead the future of immunotherapies for patients.
  • Our protein engineering expertise allows us to reimagine the development of pro-inflammatory cytokine-based therapeutics that could address the key limitations with current cancer immunotherapies.
  • Goodwin Procter LLP and Arthur Cox LLP are serving as legal counsel to Mural Oncology.

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Retrieved on: 
Friday, November 3, 2023
Molecule, TILS, Șaeș, Capillary leak syndrome, Arthralgia, Half-life, Biomarker, Therapy, CD4, UPR, PD-1, IL-2, Immunity, Phenotype, Protein, CD8, Pharmacokinetics, Mouse, SITC, Immunotherapy, Plasma, B cell, RDE, NK, Neoplasm, Annual general meeting, Tumor microenvironment, Toxic epidermal necrolysis, Safety, Society, Cancer, Patient, Toxicity, Abstract, Therapeutic index, Fatigue, Pharmaceutical industry, Vaccine

This clinical program is an ongoing, multi-center Phase 1/1b clinical trial of WTX-124, Werewolf’s interleukin 2 (IL-2) INDUKINE molecule, in patients with advanced or metastatic solid tumors.

Key Points: 
  • This clinical program is an ongoing, multi-center Phase 1/1b clinical trial of WTX-124, Werewolf’s interleukin 2 (IL-2) INDUKINE molecule, in patients with advanced or metastatic solid tumors.
  • The preliminary data will be presented today at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, California.
  • The preliminary data include data collected as of October 18, 2023, from 16 heavily pretreated patients from the first four monotherapy dose escalation cohorts (1, 3, 6, 12 mg).
  • The preliminary data established proof of mechanism for WTX-124 and proof of concept for Werewolf’s INDUKINE design.

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Retrieved on: 
Tuesday, October 31, 2023
ACT, Molecule, Survival, ET, Plasma, Half-life, Therapy, Biomarker, Renal cell carcinoma, CD19, Pembrolizumab, TM, PD-1, IL-2, Immunity, Neoplasm, Poster, CD8, Pharmacokinetics, Mouse, SITC, Immunotherapy, Syngenic, Webcast, Abstract, Annual general meeting, Flow cytometry, Tumor microenvironment, Lung cancer, Safety, Society, Cancer, Patient, Human, Therapeutic index, Toxicity, Vaccine, Pharmaceutical industry

Additional posters representing an expansive body of data demonstrating the potential of Werewolf’s PREDATOR™ platform and INDUKINE™ product candidates will also be presented.

Key Points: 
  • Additional posters representing an expansive body of data demonstrating the potential of Werewolf’s PREDATOR™ platform and INDUKINE™ product candidates will also be presented.
  • Additional posters with preclinical data supporting the PREDATOR platform and INDUKINE product candidates will also be presented at the meeting.
  • These data will provide early insight into the profile of WTX-124 and preferential activation through our INDUKINE design, including additional data since the abstract submission in June,” said Randi Isaacs, M.D., Chief Medical Officer of Werewolf.
  • Pharmacokinetic data as of June 22, 2023, demonstrated WTX-124 sustained prodrug exposure in plasma with low levels of active IL-2.

Synthekine Doses First Patient in Phase 1 Clinical Trial of Orthogonal IL-2 and CD19 CAR-T Combination Therapy, STK-009 + SYNCAR-001, for Treatment of CD19+ Hematologic Malignancies

Retrieved on: 
Thursday, July 27, 2023
Oncology, Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, IL-2, Toxic shock syndrome, Therapy, CD19, Patient, Inc., Bone marrow, Vaccine, Pharmaceutical industry

Synthekine Inc ., a leader in engineered cytokine therapeutics, today announced that the first patient has been dosed in a Phase 1 clinical trial of its orthogonal IL-2 and CD19 CAR-T combination therapy, STK-009 + SYNCAR-001, in adults with relapsed or refractory CD19+ hematologic malignancies.

Key Points: 
  • Synthekine Inc ., a leader in engineered cytokine therapeutics, today announced that the first patient has been dosed in a Phase 1 clinical trial of its orthogonal IL-2 and CD19 CAR-T combination therapy, STK-009 + SYNCAR-001, in adults with relapsed or refractory CD19+ hematologic malignancies.
  • “SYNCAR-001 + STK-009 is our second clinical stage program at Synthekine and represents another key milestone in our journey to develop novel cytokine therapeutics for patients with refractory cancers,” said Debanjan Ray, chief executive officer of Synthekine.
  • “Our orthogonal IL-2 system is a unique platform that breaks new ground in the field of cell therapy.
  • These limitations have been shown to correlate with poor response and relapse, particularly in challenging hematological malignancies.

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc

Retrieved on: 
Thursday, June 1, 2023
IL-12, Interleukin, IRS, Drug development, Lead, Bristol Myers Squibb, Immunotherapy, IL-2, ALKS, Circulatory system, Form 10-K, Fibrosis, Pharmaceutical Research and Manufacturers of America, Merck, BMS, Imperial College London, Management, Nursing, Alkermes, Chemistry

DUBLIN, June 1, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that Caroline J. Loew, Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc (Mural Oncology), the new independent public company to be established upon the planned separation of Alkermes' oncology business. Dr. Loew will join Alkermes in June as a strategic advisor and transition to CEO of Mural Oncology upon completion of the separation. 

Key Points: 
  • DUBLIN, June 1, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that Caroline J. Loew, Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc (Mural Oncology), the new independent public company to be established upon the planned separation of Alkermes' oncology business.
  • Dr. Loew will join Alkermes in June as a strategic advisor and transition to CEO of Mural Oncology upon completion of the separation.
  • "I'm delighted that we have appointed someone of Dr. Loew's caliber and scientific pedigree for the Mural Oncology CEO role.
  • Upon completion of the planned separation, Mural Oncology plc is expected to be a Nasdaq listed company, trading under the ticker symbol MURA.

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc

Retrieved on: 
Thursday, June 1, 2023
IL-12, Interleukin, IRS, Drug development, Lead, Bristol Myers Squibb, Immunotherapy, IL-2, ALKS, Circulatory system, Form 10-K, Fibrosis, Pharmaceutical Research and Manufacturers of America, Merck, BMS, Imperial College London, Management, Nursing, Alkermes, Chemistry

DUBLIN, June 1, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that Caroline J. Loew, Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc (Mural Oncology), the new independent public company to be established upon the planned separation of Alkermes' oncology business. Dr. Loew will join Alkermes in June as a strategic advisor and transition to CEO of Mural Oncology upon completion of the separation. 

Key Points: 
  • DUBLIN, June 1, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that Caroline J. Loew, Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc (Mural Oncology), the new independent public company to be established upon the planned separation of Alkermes' oncology business.
  • Dr. Loew will join Alkermes in June as a strategic advisor and transition to CEO of Mural Oncology upon completion of the separation.
  • "I'm delighted that we have appointed someone of Dr. Loew's caliber and scientific pedigree for the Mural Oncology CEO role.
  • Upon completion of the planned separation, Mural Oncology plc is expected to be a Nasdaq listed company, trading under the ticker symbol MURA.

ASLAN Pharmaceuticals Presents New Data on Eblasakimab and Farudodstat in Two Late-Breaking Presentations at the 1st International Societies for Investigative Dermatology Meeting

Retrieved on: 
Monday, May 15, 2023
Learning, Hair, IL-12, ISID, ASLN, Research fellow, TARC, HF, DHODH, MHC, HFS, IP-10, Atopic dermatitis, Research, Inflammation, IP, Publication, Associate, Immune privilege, II, IL-2, Alopecia areata, Organization, Patient, International Society for Traumatic Stress Studies, SAN, Autoimmune disease, GM-CSF, Epithelium, MHC-II, Cytokine, AD, T helper cell, Johns Hopkins School of Medicine, Vaccine, Pharmaceutical industry, Dermatology, TH1, AA

“This late-breaking data offers new and important insights into the novel mechanisms of eblasakimab and farudodstat for atopic dermatitis (AD) and alopecia areata (AA) respectively," said Dr Ferda Cevikbas, Head of Translational Science at ASLAN Pharmaceuticals.

Key Points: 
  • “This late-breaking data offers new and important insights into the novel mechanisms of eblasakimab and farudodstat for atopic dermatitis (AD) and alopecia areata (AA) respectively," said Dr Ferda Cevikbas, Head of Translational Science at ASLAN Pharmaceuticals.
  • “Furthermore, data from an ex vivo human AA disease model demonstrates the potential for farudodstat to protect against immune privilege collapse in AA.
  • This study investigated whether farudodstat, a DHODH inhibitor, has potential in the treatment of AA using an innovative ex vivo model for AA.
  • Together, the findings highlight the potential for farudodstat as a novel therapy for AA.

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results

Retrieved on: 
Tuesday, May 9, 2023
PK, Journal of Clinical Oncology, Abstract, PD, Anticipation, Pharming, Cancer, G&A, NK, Cell, Part, IL-2, ASCO, Journal, American Society of Clinical Oncology, Patient, Administration, Melanoma, Annual general meeting, TME, R, Therapy, Tumor microenvironment, Society, FC, Safety, Pharmaceutical industry, Vaccine, Medical imaging, Cryptocurrency

WALTHAM, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Xilio anticipates reporting preliminary anti-tumor activity, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from the Phase 1/2 clinical trial in the third quarter of 2023.
  • Xilio anticipates reporting preliminary safety data from the Phase 1 clinical trial into at least the third dose level in the fourth quarter of 2023.
  • Xilio plans to report additional preliminary Phase 1 safety, PK, PD, and anti-tumor activity data by the end of the second quarter of 2023.
  • Net Loss: Net loss was $22.6 million for the quarter ended March 31, 2023, compared to $21.4 million for the quarter ended March 31, 2022.

Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023

Retrieved on: 
Monday, April 17, 2023
AACR, TNF, ITGB6, Neutrophil, Basophil, CRS, Therapeutic index, Pharmacokinetics, American Association for Cancer Research, Quality of life, IL-6, Head, Toxicity, Prostate, Neck, Lung, IL-2, Cytokine release syndrome, Patient, IL-8, SAN, Coagulation, Neoplasm, Lymphocyte, Research, Therapy, Tumor microenvironment, Vaccine

“TROP2 and ITGB6 are tumor targets that are overexpressed in numerous solid tumor types and have demonstrated clinical utility when targeted as antibody drug conjugates,” said Luke Walker, M.D., Chief Medical Officer of Harpoon Therapeutics.

Key Points: 
  • “TROP2 and ITGB6 are tumor targets that are overexpressed in numerous solid tumor types and have demonstrated clinical utility when targeted as antibody drug conjugates,” said Luke Walker, M.D., Chief Medical Officer of Harpoon Therapeutics.
  • “However, significant unmet needs remain as both the depth and the durability of response with antibody drug conjugates are typically limited.
  • For more details about the AACR Annual Meeting, please visit:
    The posters will be available on Harpoon’s website following today’s presentations.
  • This spatial control of activation may address on-target tissue damage, hence enabling an expansion of the T cell engager target space.